$400M Convertible Notes Offering Proposed by Indivior, Funds to Repay Debt & Buy Back Shares
INDV has more than doubled off its 52-week low of $8.64.
Summary
Indivior Pharmaceuticals announced a proposed offering of $400 million in convertible senior notes due 2031, with an option for initial purchasers to acquire an additional $60 million. This significant financing event, representing nearly 10% of the company's market capitalization, aims to strategically manage its capital structure. Proceeds are primarily earmarked for repaying approximately $239 million in existing term loan debt, which will strengthen the balance sheet. Additionally, Indivior plans to use up to $75 million of the proceeds to repurchase common stock concurrently with the offering, which could help offset potential dilution from the convertible notes and support the stock price. The remaining funds will be allocated for general corporate purposes. Traders will closely watch the final pricing and terms of the notes, as well as the execution of the share repurchase, for their impact on the company's financial health and stock performance.
At the time of this announcement, INDV was trading at $31.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $8.64 to $38.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.